Compounds > cyclosporine

cyclosporine and ER-Negative PR-Negative HER2-Negative Breast Cancer

cyclosporine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Abduh, MS1
Alves Pereira Zóia, M; Colaço Ramos, CM; de Oliveira Beserra, A; França Matias Colombo, B; Gonçalves de Araújo, T; Goss Santos, T; Goulart, LR; Oliani, SM; Paiva Maia, YC; Piana de Andrade, V; Soares, FA; Teixeira Soares Mota, S; Van Petten de Vasconcelos Azevedo, F; Vecchi, L1
Boakye, CHA; Chowdhury, N; Doddapaneni, R; Godugu, C; Patel, K; Singh, M1

Other Studies

3 other study(ies) available for cyclosporine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer.
    International journal of nanomedicine, 2023, Volume: 18

    Topics: Cell Line, Tumor; Chitosan; Cyclosporine; Delayed-Action Preparations; Drug Carriers; Humans; Hyaluronan Receptors; Hyaluronic Acid; Nanoparticles; Triple Negative Breast Neoplasms

2023
Inhibition of the AnxA1/FPR1 autocrine axis reduces MDA-MB-231 breast cancer cell growth and aggressiveness in vitro and in vivo.
    Biochimica et biophysica acta. Molecular cell research, 2018, Volume: 1865, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Animals; Annexin A1; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Cyclosporine; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Mice; Mice, Nude; Middle Aged; Receptors, Formyl Peptide; Triple Negative Breast Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays

2018
Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer.
    Journal of pharmaceutical sciences, 2015, Volume: 104, Issue:12

    Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Cyclosporine; Cytochrome P-450 CYP3A Inhibitors; Dioxolanes; Docetaxel; Drug Synergism; Female; Half-Life; Humans; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Taxoids; Triple Negative Breast Neoplasms

2015